2016
DOI: 10.1016/j.techfore.2016.05.018
|View full text |Cite
|
Sign up to set email alerts
|

The knowledge production model of the New Sciences: The case of Translational Medicine

Abstract: The tremendous achievements of life sciences research in the last 40 years have brought relatively little improvements to medical practice, suggesting a deficiency of the medical innovation system in capitalizing on these fundamental advances. We argue that a major cause of the poor innovative performance is the slow adaption of the scientific system to the novel research technologies made available by the progress in the life sciences - rather than resistance of practitioners. We interpret the changes in the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 66 publications
(72 reference statements)
0
10
0
Order By: Relevance
“…However, they still face another profound challenge brought by the biological revolution, i.e. how to effectively transform latest findings in biopharma research into real R&D outputs (Lauto and Valentin, 2016). In fact, over the last two decades when advanced biotechnologies were intensively applied to the pharmaceutical R&D, the success rate of new drug development projects dramatically declined (Tierney et al, 2013;Malerba and Orsenigo, 2015).…”
Section: The Emergence Of Contract Research Organizations (Cros) In T...mentioning
confidence: 99%
See 2 more Smart Citations
“…However, they still face another profound challenge brought by the biological revolution, i.e. how to effectively transform latest findings in biopharma research into real R&D outputs (Lauto and Valentin, 2016). In fact, over the last two decades when advanced biotechnologies were intensively applied to the pharmaceutical R&D, the success rate of new drug development projects dramatically declined (Tierney et al, 2013;Malerba and Orsenigo, 2015).…”
Section: The Emergence Of Contract Research Organizations (Cros) In T...mentioning
confidence: 99%
“…In order to fully capitalise on the recent advancement in biopharma research, various R&D models, such as biopharma consortium and collaborative discovery platform, are proposed and tested (Allarakhia and Walsh, 2012;Sabatier et al, 2012;Tierney et al, 2013;Lauto and Valentin, 2016). These new models aim to introduce multiple stakeholders into the biopharma business ecosystem (Lauto and Valentin, 2016), by which firms, research institutes, and others Citation: Wu, Q. and He, Q. ( 2020) "DIY Laboratories and Business Innovation Ecosystems: The Case of Pharmaceutical Industry", Technological Forecasting & Social Change, In press.…”
Section: Integrating Diy Laboratories Into Pharmaceutical Randd Netwo...mentioning
confidence: 99%
See 1 more Smart Citation
“…This specialization in disciplinary profile was expected due to nature of the COVID-19 topic, favoring knowledge accumulation. However, it may be less conducive to technological problem-solving and innovation, which requires an interdisciplinary outlook (Gibbons et al, 1994;Lauto and Valentin, 2016;Institute of Medicine, 2005).…”
Section: Resultsmentioning
confidence: 99%
“…The analysis suggests a more productive knowledge process in which innovative firms use knowledge and information produced by external sources. Working on a related industry, Lauto and Valentin (2016) estimated a knowledge production function for what was coined the new science development model for clinical medicine, in which research can be conducted in a transnational effort, or locally. This is a very interesting distinction that may indicate the efficiency of transnational simultaneous research benefitting from a variety of conditions and its superiority to knowledge spillover of research conducted separately.…”
Section: Review Of Previous Workmentioning
confidence: 99%